PRO

The first half of 2023 has come to an end, and so far, this year has been just as action-packed as 2022. The first two quarters of the year have been full of first-of-their-kind clinical trials and psychedelic research, new businesses, failed businesses, altered perceptions, and certainly tons of passion. The second quarter, in particular, has been full of breaking news and important developments in the psychedelic sector.  There has been a lot going on in the industry this year. But, if we were to sum up the momentum into one sentence, it would be this: preparation for the commercialization of MDMA. 

The first three months of 2023 have been a whirlwind for the psychedelic industry– to say the least. Though it has been a particularly difficult quarter, it is just part of the growing pains of a novel industry. The industry had highs and lows throughout the past three months, but ultimately, things are moving in a positive direction. That might not be seen over the next few quarters or even years, but the events of this quarter are setting up the industry for long-term success– which is the ultimate goal.  

Investing in psychedelic companies has become increasingly popular in the past few years. Here at Psychedelic Invest, our goal is to connect you to the resources that you need to make educated decisions when it comes to your money.

Investing in psychedelic companies has become increasingly popular in the past few years. Here at Psychedelic Invest, our goal is to connect you to the resources that you need to make educated decisions when it comes to your money.